It was an interesting news day and biotechs even participated in the market strength today, which has not happened in a little while. I would not call the biotech action strong from a relative performance sense but it is encouraging to see them at least perform in line with the broader market. 1. Lilly(LLY) announced […]
September 25- EOD
A very interesting and odd day in the market today. Overall the market continued its weakness and biotechs were generally down. The market came back and it seemed to turn into a chop fest. I suspected that the CLVS news would have had a more negative impact on biotech sentiment but there did not seem […]
September 23rd EOD
It was a weak day in biotech (although it seemed to recover a little in the afternoon) and some of the biggest biotech bulls are turning cautious. Mike King of JMP was out with a note this morning talking about taking money off the table. He is still a long term biotech bull but thinks […]
September 20- Daily Update – SRPT
Obviously the big news of the day was the failure of drisapersen in their phase III trial and what it means for etperlirsen and SRPT. While it is not clear if this was RNA related but biotechs were generally weak, although not dramatically so. Before diving into the drisapersen, I want to touch on a […]
September 19- EOD
It was a relatively quiet news day. I was not sure there would be much to write about and there is nothing really new or compelling. There are some quick hitters for today and hopefully we can get some more news going tomorrow and next week. 1. I wrote a response to the ARIA bear […]
September 18- EOD
It was Fed day today, so the market was very macro driven in terms of price action. The Bernank doubled down on easing, which was a good macro environment. That being said biotechs were more mixed. I am actually starting to look at biopharma as more QE will likely lead to yield chasing. There were […]
September 18- EOD
It was Fed day today, so the market was very macro driven in terms of price action. The Bernank doubled down on easing, which was a good macro environment. That being said biotechs were more mixed. I am actually starting to look at biopharma as more QE will likely lead to yield chasing. There were […]
September 18- EOD
It was Fed day today, so the market was very macro driven in terms of price action. The Bernank doubled down on easing, which was a good macro environment. That being said biotechs were more mixed. I am actually starting to look at biopharma as more QE will likely lead to yield chasing. There were […]
September 17- EOD
Not a lot of stock specific news but some interesting larger biotech developments. The market held up better than I thought given yesterday’s close and biotechs seemed like slight underperformers but not to the same degree as yesterday. That being said I think the CLVS news seemed to bring in some buyers, so they ended […]
September 16- EOD
It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]
September 16- EOD
It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]
September 16- EOD
It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]
September 13- EOD
Generally a mixed day in biotech land today with some interesting stock specific moves but nothing really dramatic in terms of news. Looks like a quiet end to the week with stocks essentially performing in line with the broader market. 1. ECYT was up nicely today on the back of a Seeking Alpha article by […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 11- Morning
This is both an early and short report for today as I am on sick child duty for the day. Luckily it was not a particularly newsy morning and if there is something particularly compelling I will write a short note this evening. 1. I did want to follow up on the SGMO abstracts that […]
September 10- EOD
Decent day in the market but biotechs did not seem to participate to the same extent. Of course, I do not have much time to follow the market on Tuesday but today seemed more like a consolidation day for biotechs than a follow through. There was a decent amount of red on my screen with […]
September 9- EOD
Some interesting news today and generally a positive market environment, although some of the recent high fliers seemed to take most of the day off. That is not completely surprising to see a pause in the moves. 1. BIOD was the stock of the weekend (and morning) given that they released what was originally argued […]
September 6- EOD
The week ended with some interesting action and volatility over Syria news. The markets appear jumpy but note that the sell off was over the words of Putin. I think a limited American led strike is basically accepted and priced in but the key will be the response. If Syria (and Russia/Iran) accept it and […]
